The Claim

Once-weekly exenatide does not reduce the risk of developing diabetic retinopathy in adults with type 2 diabetes, with no significant difference in retinopathy incidence between treatment and placebo groups, independent of baseline retinopathy status or degree of HbA1c reduction.

Source: Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
82score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

Taking a weekly exenatide shot doesn’t lower the chance of eye problems from diabetes, even if your blood sugar improves or you already had early eye issues.

See the scientific wording

Once-weekly exenatide does not reduce the risk of developing retinopathy in adults with type 2 diabetes, with no significant difference in retinopathy rates between treatment and placebo groups, regardless of prior retinopathy status or degree of HbA1c lowering.

What the research says

1 study

  1. Study: Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial

    The study looked at whether a diabetes drug called once-weekly exenatide helps prevent eye problems, and found it didn’t make a difference compared to a placebo, which supports the claim.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.